鼻内抗组胺药和皮质类固醇治疗过敏性鼻炎:系统综述和荟萃分析。

IF 11.4 1区 医学 Q1 ALLERGY
{"title":"鼻内抗组胺药和皮质类固醇治疗过敏性鼻炎:系统综述和荟萃分析。","authors":"","doi":"10.1016/j.jaci.2024.04.016","DOIUrl":null,"url":null,"abstract":"<div><h3>Background</h3><p>There is insufficient systematized evidence on the effectiveness of individual intranasal medications in allergic rhinitis (AR).</p></div><div><h3>Objectives</h3><p>We sought to perform a systematic review to compare the efficacy of individual intranasal corticosteroids and antihistamines against placebo in improving the nasal and ocular symptoms and the rhinoconjunctivitis-related quality of life of patients with perennial or seasonal AR.</p></div><div><h3>Methods</h3><p>The investigators searched 4 electronic bibliographic databases and 3 clinical trials databases for randomized controlled trials (1) assessing adult patients with seasonal or perennial AR and (2) comparing the use of intranasal corticosteroids or antihistamines versus placebo. Assessed outcomes included the Total Nasal Symptom Score, the Total Ocular Symptom Score, and the Rhinoconjunctivitis Quality-of-Life Questionnaire. The investigators performed random-effects meta-analyses of mean differences for each medication and outcome. The investigators assessed evidence certainty using the GRADE (Grading of Recommendations, Assessment, Development and Evaluation) approach.</p></div><div><h3>Results</h3><p>This review included 151 primary studies, most of which assessed patients with seasonal AR and displayed unclear or high risk of bias. Both in perennial and seasonal AR, most assessed treatments were more effective than placebo. In seasonal AR, azelastine-fluticasone, fluticasone furoate, and fluticasone propionate were the medications with the highest probability of resulting in moderate or large improvements in the Total Nasal Symptom Score and Rhinoconjunctivitis Quality-of-Life Questionnaire. Azelastine-fluticasone displayed the highest probability of resulting in moderate or large improvements of Total Ocular Symptom Score. Overall, evidence certainty was considered “high” in 6 of 46 analyses, “moderate” in 23 of 46 analyses, and “low”/“very low” in 17 of 46 analyses.</p></div><div><h3>Conclusions</h3><p>Most intranasal medications are effective in improving rhinitis symptoms and quality of life. However, there are relevant differences in the associated evidence certainty.</p></div>","PeriodicalId":14936,"journal":{"name":"Journal of Allergy and Clinical Immunology","volume":null,"pages":null},"PeriodicalIF":11.4000,"publicationDate":"2024-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S0091674924004196/pdfft?md5=793b1b7e38229ba28421b97f34d74eaf&pid=1-s2.0-S0091674924004196-main.pdf","citationCount":"0","resultStr":"{\"title\":\"Intranasal antihistamines and corticosteroids in allergic rhinitis: A systematic review and meta-analysis\",\"authors\":\"\",\"doi\":\"10.1016/j.jaci.2024.04.016\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<div><h3>Background</h3><p>There is insufficient systematized evidence on the effectiveness of individual intranasal medications in allergic rhinitis (AR).</p></div><div><h3>Objectives</h3><p>We sought to perform a systematic review to compare the efficacy of individual intranasal corticosteroids and antihistamines against placebo in improving the nasal and ocular symptoms and the rhinoconjunctivitis-related quality of life of patients with perennial or seasonal AR.</p></div><div><h3>Methods</h3><p>The investigators searched 4 electronic bibliographic databases and 3 clinical trials databases for randomized controlled trials (1) assessing adult patients with seasonal or perennial AR and (2) comparing the use of intranasal corticosteroids or antihistamines versus placebo. Assessed outcomes included the Total Nasal Symptom Score, the Total Ocular Symptom Score, and the Rhinoconjunctivitis Quality-of-Life Questionnaire. The investigators performed random-effects meta-analyses of mean differences for each medication and outcome. The investigators assessed evidence certainty using the GRADE (Grading of Recommendations, Assessment, Development and Evaluation) approach.</p></div><div><h3>Results</h3><p>This review included 151 primary studies, most of which assessed patients with seasonal AR and displayed unclear or high risk of bias. Both in perennial and seasonal AR, most assessed treatments were more effective than placebo. In seasonal AR, azelastine-fluticasone, fluticasone furoate, and fluticasone propionate were the medications with the highest probability of resulting in moderate or large improvements in the Total Nasal Symptom Score and Rhinoconjunctivitis Quality-of-Life Questionnaire. Azelastine-fluticasone displayed the highest probability of resulting in moderate or large improvements of Total Ocular Symptom Score. Overall, evidence certainty was considered “high” in 6 of 46 analyses, “moderate” in 23 of 46 analyses, and “low”/“very low” in 17 of 46 analyses.</p></div><div><h3>Conclusions</h3><p>Most intranasal medications are effective in improving rhinitis symptoms and quality of life. However, there are relevant differences in the associated evidence certainty.</p></div>\",\"PeriodicalId\":14936,\"journal\":{\"name\":\"Journal of Allergy and Clinical Immunology\",\"volume\":null,\"pages\":null},\"PeriodicalIF\":11.4000,\"publicationDate\":\"2024-08-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://www.sciencedirect.com/science/article/pii/S0091674924004196/pdfft?md5=793b1b7e38229ba28421b97f34d74eaf&pid=1-s2.0-S0091674924004196-main.pdf\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Journal of Allergy and Clinical Immunology\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://www.sciencedirect.com/science/article/pii/S0091674924004196\",\"RegionNum\":1,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q1\",\"JCRName\":\"ALLERGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of Allergy and Clinical Immunology","FirstCategoryId":"3","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S0091674924004196","RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"ALLERGY","Score":null,"Total":0}
引用次数: 0

摘要

背景:目前还没有足够的系统证据表明单种鼻内用药对过敏性鼻炎(AR)的疗效:进行一项系统性研究,比较单个鼻内皮质类固醇激素和抗组胺药与安慰剂在改善常年性或季节性过敏性鼻炎患者的鼻部和眼部症状以及与鼻结膜炎相关的生活质量方面的疗效:我们在四个电子文献数据库和三个临床试验数据库中搜索了以下随机对照试验:(i) 评估季节性或常年性 AR 成年患者的试验;(ii) 比较鼻内皮质类固醇激素或抗组胺药与安慰剂的使用情况。评估的结果包括鼻部症状总评分(TNSS)、眼部症状总评分(TOSS)和鼻结膜炎生活质量问卷(RQLQ)。我们对每种药物和结果的平均差异进行了随机效应荟萃分析。我们采用 GRADE 方法评估了证据的确定性:我们纳入了 151 项主要研究,其中大部分研究评估的是季节性 AR 患者,偏倚风险不明确或较高。无论是常年性还是季节性AR,大多数评估的治疗方法都比安慰剂更有效。在季节性 AR 中,阿折司亭-氟替卡松、糠酸氟替卡松和丙酸氟替卡松是最有可能使 TNSS 和 RQLQ 中度或大幅改善的药物。阿折拉斯汀-氟替卡松导致 TOSS 中度或大幅改善的概率最高。总体而言,6/46 项分析认为证据确定性 "高",23/46 项分析认为证据确定性 "中等",17/46 项分析认为证据确定性 "低"/"极低":结论:大多数鼻内用药都能有效改善鼻炎症状和生活质量。然而,相关证据的确定性存在相关差异。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
Intranasal antihistamines and corticosteroids in allergic rhinitis: A systematic review and meta-analysis

Background

There is insufficient systematized evidence on the effectiveness of individual intranasal medications in allergic rhinitis (AR).

Objectives

We sought to perform a systematic review to compare the efficacy of individual intranasal corticosteroids and antihistamines against placebo in improving the nasal and ocular symptoms and the rhinoconjunctivitis-related quality of life of patients with perennial or seasonal AR.

Methods

The investigators searched 4 electronic bibliographic databases and 3 clinical trials databases for randomized controlled trials (1) assessing adult patients with seasonal or perennial AR and (2) comparing the use of intranasal corticosteroids or antihistamines versus placebo. Assessed outcomes included the Total Nasal Symptom Score, the Total Ocular Symptom Score, and the Rhinoconjunctivitis Quality-of-Life Questionnaire. The investigators performed random-effects meta-analyses of mean differences for each medication and outcome. The investigators assessed evidence certainty using the GRADE (Grading of Recommendations, Assessment, Development and Evaluation) approach.

Results

This review included 151 primary studies, most of which assessed patients with seasonal AR and displayed unclear or high risk of bias. Both in perennial and seasonal AR, most assessed treatments were more effective than placebo. In seasonal AR, azelastine-fluticasone, fluticasone furoate, and fluticasone propionate were the medications with the highest probability of resulting in moderate or large improvements in the Total Nasal Symptom Score and Rhinoconjunctivitis Quality-of-Life Questionnaire. Azelastine-fluticasone displayed the highest probability of resulting in moderate or large improvements of Total Ocular Symptom Score. Overall, evidence certainty was considered “high” in 6 of 46 analyses, “moderate” in 23 of 46 analyses, and “low”/“very low” in 17 of 46 analyses.

Conclusions

Most intranasal medications are effective in improving rhinitis symptoms and quality of life. However, there are relevant differences in the associated evidence certainty.

求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
CiteScore
25.90
自引率
7.70%
发文量
1302
审稿时长
38 days
期刊介绍: The Journal of Allergy and Clinical Immunology is a prestigious publication that features groundbreaking research in the fields of Allergy, Asthma, and Immunology. This influential journal publishes high-impact research papers that explore various topics, including asthma, food allergy, allergic rhinitis, atopic dermatitis, primary immune deficiencies, occupational and environmental allergy, and other allergic and immunologic diseases. The articles not only report on clinical trials and mechanistic studies but also provide insights into novel therapies, underlying mechanisms, and important discoveries that contribute to our understanding of these diseases. By sharing this valuable information, the journal aims to enhance the diagnosis and management of patients in the future.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信